In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
no speaker photo
Speaker
Marc Pfeffer
Marc Pfeffer Marc Pfeffer

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)

Speciality : Risk Factors and Prevention

31 presentations from this speaker

Old drugs in the modern era: ACEI/ARB, MRAs+digoxin.

Event : ESC Congress 2020

  • Session : Pharmacological Treatment of Chronic Heart Failure
  • Speaker : M Pfeffer (Boston,US)

Cardiovascular outcome trials of novel antidiabetic drugs: a critical analysis.

Event : Heart Failure 2019

  • Session : A crosstalk between diabetes and heart failure
  • Speaker : M Pfeffer (Boston,US)

Cardiovascular outcome trials of novel antidiabetic medications: new hope for heart failure patients?

Event : ESC Congress 2019

  • Session : Diabetes and heart failure: a complex relationship
  • Speaker : M Pfeffer (Boston,US)

Q&A - Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes.

Event : Heart Failure 2019

  • Session : Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes (EBAC Accredited)
  • Speaker : S Verma (Toronto,CA), M Cowie (London,GB), A Mebazaa (Paris,FR), M Pfeffer (Boston,US)
  • Organised by the Sahlgrenska Academy, University of Gothenburg, Sweden, supported with an educational grant from AstraZeneca. Course Director: Professor Karl Swedberg

Refining the diagnosis of HFpEF

Event : ESC Congress 2019

  • Session : New hope for HFpEF patients
  • Speaker : M Pfeffer (Boston,US)

Renin-angiotensin-aldosterone system inhibition.

Event : Heart Failure 2019

  • Session : Chronic heart failure: optimising patient management
  • Speaker : M Pfeffer (Boston,US)

What have cardiovascular outcomes trials taught us about cardiovascular risk management?

Event : Heart Failure 2019

  • Session : Sodium–glucose co-transporter 2 inhibition and the heart: lessons from cardiovascular outcomes trials in Type 2 diabetes (EBAC Accredited)
  • Speaker : M Pfeffer (Boston,US)
  • Organised by the Sahlgrenska Academy, University of Gothenburg, Sweden, supported with an educational grant from AstraZeneca. Course Director: Professor Karl Swedberg

Blood pressure - The lower, the better in heart failure

Event : Heart Failure 2018

  • Session : Medical myths about heart failure and the facts behind them
  • Speaker : M Pfeffer (Boston,US)

Clinical aspects: type 2 diabetes, cardiovascular disease and glucagon-like peptide-1 receptor agonists.

Event : ESC Congress 2018

  • Session : Discussion: Glucagon-like peptide-1 receptor agonists and changing paradigms in clinical practice
  • Speaker : M Pfeffer (Boston,US)
  • Sponsored by Novo Nordisk A/S

Heart failure as a serious but preventable complication of T2DM – cardiologist perspective.

Event : Heart Failure 2018

  • Session : Biomarker targeted approach in preventing heart failure among patients with diabetes
  • Speaker : M Pfeffer (Boston,US)
  • Sponsored by Roche

New guidance in optimizing heart failure care.

Event : ESC Congress 2018

  • Session : Optimized heart failure care throughout the patient journey
  • Speaker : M Pfeffer (Boston,US)
  • Sponsored by SERVIER

Perspective on glucagon-like peptide-1 receptor agonists in type 2 diabetes and cardiovascular disease: Interactive discussion.

Event : ESC Congress 2018

  • Session : Discussion: Glucagon-like peptide-1 receptor agonists and changing paradigms in clinical practice
  • Speaker : BM Scirica (Boston,US), S Verma (Toronto,CA), M Pfeffer (Boston,US)
  • Sponsored by Novo Nordisk A/S

Primary P value neutral- Can there be more to learn?

Event : Heart Failure 2018

  • Session : Off the record with M. Pfeffer
  • Speaker : M Pfeffer (Boston,US)

The HFA Eugene Braunwald lecture - Building on concepts

Event : Heart Failure 2018

  • Session : Inaugural Session
  • Speaker : M Pfeffer (Boston,US)

The importance of blood pressure control

Event : Heart Failure 2018

  • Session : Prevention remains the best treatment in heart failure
  • Speaker : M Pfeffer (Boston,US)

A SPRINT to better prevention of heart failure.

Event : Heart Failure 2017

  • Session : How the results of recent randomized clinical trials will impact our practice
  • Speaker : M Pfeffer (Boston,US)

Glucose lowering drugs and cardiovascular outcome.

Event : Heart Failure 2017

  • Session : Hot topics in diabetes and heart failure
  • Speaker : M Pfeffer (Boston,US)

Interactive discussions - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

Event : ESC Congress 2017

  • Session : GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?
  • Speaker : L Ryden (Stockholm,SE), M Husain (Toronto,CA), M Pfeffer (Boston,US)
  • Sponsored by Novo Nordisk

Kidney dysfunction in heart failure: why worry?

Event : ESC Congress 2017

  • Session : Heart failure patients tend to have more than one problem: how to manage comorbidities
  • Speaker : M Pfeffer (Boston,US)

Translating trials into practice – Clinical implications .

Event : ESC Congress 2017

  • Session : GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?
  • Speaker : M Pfeffer (Boston,US)
  • Sponsored by Novo Nordisk

Treatment of HFpEF: drugs and devices on the horizon.

Event : ESC Congress 2017

  • Session : Heart failure with preserved ejection fraction - A clinical dilemma
  • Speaker : M Pfeffer (Boston,US)

Primary endpoint is negative, what next? A clinical perspective.

Event : ESC Congress 2016

  • Session : Interpreting clinical trials: does a primary endpoint tell it all?
  • Speaker : M Pfeffer (Boston,US)

Superiority versus non-inferiority and intention-to-treat versus on-treatment analysis - Which one to trust?

Event : ESC Congress 2016

  • Session : How to interpret statistics in clinical trials - A guide for the clinical cardiologist
  • Speaker : M Pfeffer (Boston,US)

ACE Inhibition.

Event : Heart Failure 2015

  • Session : The success of neurohormonal blockade: looking back – looking forward
  • Speaker : M Pfeffer (Boston,US)

Aldosterone antagonism for diastolic heart failure – where do we stand after TOPCAT?

Event : Heart Failure 2015

  • Session : New developments and controversial issues in heart failure
  • Speaker : M Pfeffer (Boston,US)

Do global trials really meet global needs?

Event : ESC Congress 2015

  • Session : Do current clinical trials meet society needs?
  • Speaker : M Pfeffer (Boston,US)

Future directions.

Event : Heart Failure 2015

  • Session : Heart failure in tomorrow’s world
  • Speaker : M Pfeffer (Boston,US)

Prevention is the best treatment.

Event : Heart Failure 2015

  • Session : The global heart failure epidemic
  • Speaker : M Pfeffer (Boston,US)

Good trial or bad trial? What do I need to look at.

Event : ESC Congress 2014

  • Session : How to understand clinical trials: statistics don't bite
  • Speaker : M Pfeffer (Boston,US)

Acute heart failure and Type 2 diabetes mellitus.

Event : ESC Congress 2013

  • Session : Heart failure across the spectrum of glucose intolerance
  • Speaker : M Pfeffer (Boston,US)

Panel.

Event : ESC Congress 2013

  • Session : Heart failure across the spectrum of glucose intolerance
  • Speaker : M Mamas (Stoke On Trent,GB), M Pfeffer (Boston,US), J Spinar (Brno,CZ)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are